Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cytopenia
- Acute Lymphoblastic Leukemia
- Anemia, Aplastic
- Anemia, Sickle Cell
- Diamond Blackfan Anemia
- Fanconi Anemia
- ? Thalassemia
- Hemoglobinopathies
- Leukemia, Acute Myeloid (AML), Child
- Lymphoma Non-Hodgkin
- Myelodysplastic Syndromes
- Primary Immunodeficiency
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 118 years
- Gender
- Both males and females
Description
Subjects enrolled on the BP-004 study who have completed or discontinued from the study, and are beyond Day 180 will be requested to enroll on this long-term follow up protocol. Long term follow up for gene therapy clinical and safety endpoints will continue up to 15 years.
Subjects enrolled on the BP-004 study who have completed or discontinued from the study, and are beyond Day 180 will be requested to enroll on this long-term follow up protocol. Long term follow up for gene therapy clinical and safety endpoints will continue up to 15 years.
Tracking Information
- NCT #
- NCT03733249
- Collaborators
- Not Provided
- Investigators
- Study Director: Bellicum Pharmaceuticals Bellicum Pharmaceuticals, Inc.
Get Well Soon